All Oncology News

A supplemental biologics license application has been submitted to the FDA for ofatumumab as a maintenance therapy in patients with relapsed chronic lymphocytic leukemia following a response to second- or third-line therapy.

A supplemental new drug application has been submitted for carfilzomib (Kyprolis) in combination with dexamethasone for patients with relapsed multiple myeloma following prior treatment with at least one therapy.

OncLive  editorial, marketing teams will share news about Sylvester Center.

The FDA has granted a breakthrough therapy designation to the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib as a potential treatment for patients with BRAFV600E-mutant non-small cell lung cancer.

Women with ovarian cancer who experienced an average dose reduction of ≤85% had a 35% higher mortality risk than those who received normal dosing.

Treatment with the combination of selumetinib and dacarbazine failed to improve progression-free survival compared with dacarbazine alone in patients with metastatic uveal melanoma.

Mohammad Jahanzeb, MD, discusses impactful studies and other key issues in HER2-positive breast cancer.

The European Commission has approved the PD-1 inhibitor pembrolizumab as a treatment for adult patients with unresectable or metastatic melanoma in the first-line and previously treated settings.

An appellate court ruled that the FDA-approved biosimilar Zarxio can be marketed in the United States after September 2, 2015.

Douglas Yee, MD, explains current treatment options and ongoing research aimed at optimizing neoadjuvant therapy for HER2-positive breast cancer.

The European Commission has approved nivolumab as a treatment for patients with locally advanced or metastatic squamous non–small cell lung cancer following prior chemotherapy.

The phase III CheckMate-025 trial has been halted after an independent panel determined that nivolumab improved overall survival versus everolimus in patients with advanced renal cell carcinoma.

Treatment with cabozantinib improved progression-free survival and overall survival compared with everolimus in pretreated patients with metastatic renal cell carcinoma.

Innovative models for palliative care delivery and primary palliative care training are springing up to address the demand–capacity mismatch.

Robert Coleman, MD, discusses a potential new biomarker for PARP inhibition in ovarian cancer that was examined in the ARIEL2 trial.

The FDA has granted an orphan drug designation to the immunotherapy DPX-Survivac as a treatment for women with ovarian cancer.

Monotherapy with blinatumomab has demonstrated promising complete remission (CR) or CR with partial hematological recovery (CRh) rates in adult patients with relapsed or refractory Philadelphia chromosome-positive (Ph+) B-cell precursor acute lymphoblastic leukemia.

Philip Philip, MD, PhD, discusses how MM-398 and other emerging therapies are offering new hope to patients with pancreatic cancer.

PIK3CA mutations and low/no expression of PTEN correlated with an extension in progression-free survival for patients with metastatic HER2-positive breast cancer treated with the combination of everolimus, trastuzumab, and paclitaxel.

Focus will be on Wisconsin Center's innovative research centers and impact on local communities.

Eric Van Cutsem, MD, PhD, discusses results from the phase IIIb CONSIGN study and the continuing advance of precision medicine in colorectal cancer.

James J. Lee, MD, PhD, discusses research into mismatch repair deficiency as a biomarker for PD-1 inhibition in colorectal cancer.

A new drug application has been submitted for the oral proteasome inhibitor ixazomib in combination with lenalidomide and dexamethasone as a treatment for patients with relapsed and/or refractory multiple myeloma

OncLive® and UPMC CancerCenter, partner with University of Pittsburgh Cancer Institute, have teamed up under OncLive's Strategic Alliance Partnership program.

A collection of early phase clinical trials presented at the 2015 ASCO Annual Meeting demonstrated promising results for several novel agents in combination with established treatments for patients with hepatocellular carcinoma.

The FDA approved gefitinib for the frontline treatment of patients with metastatic, EGFR-positive non-small cell lung cancer.

Second-line treatment with atezolizumab (MPDL3280A) has met the primary endpoint of a pivotal phase II study by effectively shrinking tumors in patients with locally advanced or metastatic urothelial bladder cancer.

Michael P. Manns, MD, discusses the relationship between advances in hepatitis C care and the future of HCC treatment.

As the 340B drug discount program has ballooned in size over the last several years, some hospitals are getting creative about how to make the program work for their own financial gain.

Stephen Liu, MD, discusses the results and purpose of the uniquely designed trial examining atezolizumab in combination with platinum-based doublet chemotherapy in treatment-naïve patients with advanced non–small cell lung cancer.